transplant rejection

The firm moved closer to commercializing its lung transplant test, and it was notified by New York State that it could begin testing patient samples using its DTC celiac disease test.

CareDx said it will add XynManagement's products to its digital solutions portfolio and integrate them with current offerings including OTTR.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.

The diagnostic will now be a contracted service with Anthem Blue Cross of California and 10 of its affiliated health plans.

The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.

The acquisition of OTTR Complete Transplant Management will enable CareDx to integrate the EMRs of patients at transplant centers with longitudinal patient surveillance data.

The company filed its first suit against Natera in March, claiming the firm's kidney transplant test infringes patents underlying CareDx's AlloSure test.